References:
1 Calsolaro, V. & Edison, P. Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement 12, 719-732, doi:10.1016/j.jalz.2016.02.010 (2016).
2 Datta, G. et al. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. Brain 140, 2927-2938, doi:10.1093/brain/awx228 (2017).
3 Illig, C. R. et al. Discovery of novel FMS kinase inhibitors as anti-inflammatory agents. Bioorg Med Chem Lett 18, 1642-1648, doi:10.1016/j.bmcl.2008.01.059 (2008).
4 Reilly, J. F. et al. Amyloid deposition in the hippocampus and entorhinal cortex: quantitative analysis of a transgenic mouse model. Proc Natl Acad Sci U S A 100, 4837-4842, doi:10.1073/pnas.0330745100 (2003).
5 Melnikova, T. et al. Reversible pathologic and cognitive phenotypes in an inducible model of Alzheimer-amyloidosis. J Neurosci 33, 3765-3779, doi:10.1523/JNEUROSCI.4251-12.2013 (2013).
6 Boza-Serrano, A., Yang, Y., Paulus, A. & Deierborg, T. Innate immune alterations are elicited in microglial cells before plaque deposition in the Alzheimer's disease mouse model 5xFAD. Sci Rep 8, 1550, doi:10.1038/s41598-018-19699-y (2018).
7 Kreisl, W. C. Discerning the relationship between microglial activation and Alzheimer's disease. Brain 140, 1825-1828, doi:10.1093/brain/awx151 (2017).
8 Fan, Z., Brooks, D. J., Okello, A. & Edison, P. An early and late peak in microglial activation in Alzheimer's disease trajectory. Brain 140, 792-803, doi:10.1093/brain/aww349 (2017).